BR112020019624A8 - Método para tratar a hipoglicemia pós-prandial - Google Patents

Método para tratar a hipoglicemia pós-prandial

Info

Publication number
BR112020019624A8
BR112020019624A8 BR112020019624A BR112020019624A BR112020019624A8 BR 112020019624 A8 BR112020019624 A8 BR 112020019624A8 BR 112020019624 A BR112020019624 A BR 112020019624A BR 112020019624 A BR112020019624 A BR 112020019624A BR 112020019624 A8 BR112020019624 A8 BR 112020019624A8
Authority
BR
Brazil
Prior art keywords
postprandial hypoglycemia
hypoglycemia
treat
treat postprandial
postprandial
Prior art date
Application number
BR112020019624A
Other languages
English (en)
Other versions
BR112020019624A2 (pt
Inventor
Bentley Cheatham
T Green James
William Wilkison
Original Assignee
Avolynt
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avolynt, Kissei Pharmaceutical filed Critical Avolynt
Publication of BR112020019624A2 publication Critical patent/BR112020019624A2/pt
Publication of BR112020019624A8 publication Critical patent/BR112020019624A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

método para tratar a hipoglicemia pós-prandial. são divulgados aqui métodos, compostos transportadores de glicose dependentes de sódio (sglt) 1 e composições para o tratamento da hipoglicemia pós-prandial, hipoglicemia pós-prandial que ocorre como uma consequência da cirurgia gástrica.
BR112020019624A 2018-03-28 2019-03-28 Método para tratar a hipoglicemia pós-prandial BR112020019624A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649352P 2018-03-28 2018-03-28
US62/649,352 2018-03-28
PCT/US2019/024463 WO2019191352A1 (en) 2018-03-28 2019-03-28 Method for treating post-prandial hypoglycemia

Publications (2)

Publication Number Publication Date
BR112020019624A2 BR112020019624A2 (pt) 2021-01-05
BR112020019624A8 true BR112020019624A8 (pt) 2022-03-03

Family

ID=68060762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020019624A BR112020019624A8 (pt) 2018-03-28 2019-03-28 Método para tratar a hipoglicemia pós-prandial

Country Status (7)

Country Link
US (1) US11596644B2 (pt)
EP (1) EP3773546A4 (pt)
CN (1) CN112469407A (pt)
BR (1) BR112020019624A8 (pt)
CA (1) CA3094118A1 (pt)
MX (1) MX2020009349A (pt)
WO (1) WO2019191352A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CN101910189B (zh) 2007-12-27 2013-06-19 橘生药品工业株式会社 吡唑衍生物的单癸二酸盐
ES2385185T3 (es) 2008-04-16 2012-07-19 Kissei Pharmaceutical Co., Ltd. Hemifumarato de un derivado de pirazol
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
US9273085B2 (en) 2012-05-07 2016-03-01 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
DK3489226T3 (da) 2012-11-20 2021-04-26 Lexicon Pharmaceuticals Inc Hæmmere for natriumglucose-cotransporter 1

Also Published As

Publication number Publication date
MX2020009349A (es) 2021-04-28
CA3094118A1 (en) 2019-10-03
EP3773546A4 (en) 2022-02-23
BR112020019624A2 (pt) 2021-01-05
EP3773546A1 (en) 2021-02-17
US11596644B2 (en) 2023-03-07
CN112469407A (zh) 2021-03-09
WO2019191352A9 (en) 2019-11-28
US20210085701A1 (en) 2021-03-25
WO2019191352A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
PH12020550901A1 (en) Macrocyclic compounds for treating disease
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
BR112017023269A2 (pt) métodos para tratamento de câncer
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
NZ731696A (en) Method for treating cancer
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
BR112021018456A2 (pt) Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
MX2021015235A (es) Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni.
CY1124688T1 (el) Θεραπεια πρωτεϊνουριας
CL2017000873A1 (es) Composiciones y métodos para mejorar la movilidad o actividad o tratar la fragilidad
BR112017016110A2 (pt) composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus
EA202092824A1 (ru) Комбинированная терапия
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
BR112019005825A2 (pt) vírus envelopado modificado, composição farmacêutica, e, método para tratar um câncer
MX2021008716A (es) Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina.

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: AVOLYNT (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA DE PARTE DOS DIREITOS, REQUERIDA ATRAVES DA PETICAO NO 870210034240 DE 15/04/2021, E NECESSARIO APRESENTAR DOCUMENTO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, TRADUCAO JURAMENTADA, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: AVOLYNT (US) ; KISSEI PHARMACEUTICAL CO., LTD (JP)

Free format text: ANULADA A PUBLICACAO CODIGO 25.3 NA RPI NO 2641 DE 17/08/2021 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B25B Requested transfer of rights rejected

Owner name: AVOLYNT (US) ; KISSEI PHARMACEUTICAL CO., LTD (JP)

Free format text: INDEFERIDO O PEDIDO DE INCLUSAO DE TITULAR CONTIDO NA PETICAO 870210034240 DE 15/04/2021, EM VIRTUDE DO PEDIDO JA ESTAR EM NOME DOS DOIS INTERESSADOS.

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]